Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the quarter and nine months ended September 30, 2002. Gilead is an independent biopharmaceutical company focused on antivirals, antibacterials, and antifungals. Key products include Viread (HIV), AmBisome (antifungal), and Hepsera (hepatitis B). The company operates globally with significant revenue exposure to European markets.
Key Financial Metrics
| Metric | Q3 2002 | Q3 2001 | 9M 2002 | 9M 2001 |
|---|---|---|---|---|
| Total Revenues | $134.0M | $50.9M | $321.8M | $159.4M |
| Net Income (Loss) | $20.8M | ($25.2M) | $36.6M | ($79.3M) |
| EPS (Diluted) | $0.10 | ($0.13) | $0.18 | ($0.41) |
| Operating Cash Flow (9M) | $38.9M (vs. ($92.8M) in 2001) | |||
| Cash & Marketable Securities | $624.8M (as of Sept 30, 2002) | |||
| Long-Term Debt | $250.0M (5% Convertible Notes due 2007) | |||
| Product Gross Margin | 83.0% | 79.4% | 82.4% (9M) | 76.7% (9M) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased 163% in Q3 and 102% for the nine months compared to 2001. This is primarily driven by Viread sales, which reached $68.9M in Q3 (57% of product sales) and $140.8M for the nine months. Viread was not approved until October 2001, resulting in minimal comparable sales in 2001.
- Profitability Turnaround: The company reported net income of $20.8M for Q3 2002, a reversal from a net loss of $25.2M in Q3 2001. Operating income improved from a loss of $36.1M to a profit of $35.9M.
- Expense Management: R&D expenses decreased 23% in Q3 and 29% for the nine months, attributed to the divestiture of the oncology program to OSI Pharmaceuticals and reduced clinical costs for Viread post-approval. Conversely, SG&A expenses increased 32% in Q3 due to expanded sales forces for Viread and Hepsera.
- Unusual Items: A non-operating loss of $16.0M was recognized in Q3 2002 due to the sale of OSI Pharmaceuticals stock. Additionally, a $2.0M charge was recorded for the termination of the Cubist Pharmaceuticals licensing agreement.
Guidance, Outlook, and Risks
- Full Year 2002 Guidance:
- R&D Expenses: Expected to be $130M–$140M (20–30% lower than 2001).
- SG&A Expenses: Expected to be $170M–$180M (35–45% higher than 2001).
- Gross Margins: Expected to be approximately 82% for the full year.
- Liquidity: Management believes existing capital resources ($624.8M in cash/securities) are adequate for the foreseeable future. However, future funding needs depend on product performance and R&D progress.
- Key Risks:
- European Credit Risk: Significant accounts receivable ($44.9M past due) in Greece, Spain, Portugal, and Italy due to government reimbursement delays. $29.7M is over 120 days past due.
- Competition: Intense competition in HIV/AIDS (Viread) and antifungal (AmBisome) markets.
- Regulatory & Pricing: Risks related to regulatory approvals, compulsory licensing in developing countries, and government price controls.
- Accounting Reclassification: A misclassification of $38.8M in OSI stock (previously recorded as cash) was corrected. This reclassified the asset to marketable securities and adjusted prior period cash flow statements but had no impact on net income.
Investor Verification Checklist
- European Receivables: Verify the collectibility of the $44.9M in past-due receivables from European governments, particularly the $29.7M over 120 days old.
- Viread Growth Sustainability: Assess whether Viread sales growth can sustain the current revenue trajectory given the competitive HIV market landscape.
- SG&A Run Rate: Monitor if SG&A expenses remain within the guided $170M–$180M range as sales forces expand.
- Convertible Notes: Review the terms of the $250M 5% convertible notes due in 2007 and potential dilution upon conversion.
- Collaboration Milestones: Track the $30M in potential milestone payments from the GlaxoSmithKline (GSK) Hepsera licensing agreement.